Dublin, July 17, 2024 (GLOBE NEWSWIRE) -- The "Dementia with Diabetes - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Dementia with Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Dementia with Diabetes Emerging Drugs Chapters
This segment of the Dementia with Diabetes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dementia with Diabetes Emerging Drugs
Azeliragon (TTP488): vTv Therapeutics Azeliragon (TTP488) is developed by vTv Therapeutics which is currently in phase II/III clinical developmental trial in patients with mild- Alzheimer's disease in patients with type 2 diabetes. Azeliragon (TTP488) is an orally bioavailable small molecule that inhibits the receptor for advanced glycation endproduct (RAGE) being developed for dementia. RAGE is an immunoglobulin-like cell surface receptor that is overexpressed in brain tissues of patients with Alzheimer's disease. vTv Therapeutics has also received fast-track designation from the US FDA for Azeliragon in Alzheimer's disease.
Dementia with Diabetes: Therapeutic Assessment
This segment of the report provides insights about the different Dementia with Diabetes drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Dementia with Diabetes
There are approx. 5+ key companies which are developing the therapies for Dementia with Diabetes. The companies which have their Dementia with Diabetes drug candidates in the advanced stage, i.e. phase III and include, vTv Therapeutics etc.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Dementia with Diabetes R&D. The therapies under development are focused on novel approaches to treat/improve Dementia with Diabetes.
Currently, several trials with anti-diabetic drugs in AD are underway and their results are expected in the next few years. Besides, further studies exploring the molecular mechanisms underlying the favorable effects of anti-diabetic drugs in the CNS could open new perspectives on future treatments.
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Dementia with Diabetes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dementia with Diabetes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dementia with Diabetes drugs.
Key Questions
- How many companies are developing Dementia with Diabetes drugs?
- How many Dementia with Diabetes drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dementia with Diabetes?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dementia with Diabetes therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dementia with Diabetes and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- vTv Therapeutics
Key Products
- Azeliragon (TTP488)
Phases
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
Molecule Type
- Proteins and Peptides
- Small molecules
- Hormones
- Enzymes
Dementia with Diabetes Report Insights
- Dementia with Diabetes Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Dementia with Diabetes Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/obinfp
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
